A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
Abstract Breast cancer (BC), specifically HER2‐positives subtype, has a poor prognosis. Nevertheless, the development of anti‐HER2 therapy yielded satisfactory outcomes. Therefore, evaluating patient HER2 status and ascertaining responsiveness to anti‐HER2 therapy is crucial. The advent of deep lear...
Saved in:
| Main Authors: | Xinpei Deng, Yixuan Yan, Zekai Zhan, Jindong Xie, Hailin Tang, Yutian Zou, Jian Tu, Peng Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | iMetaOmics |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imo2.19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01) -
HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions
by: Dimitrios Papageorgiou, et al.
Published: (2024-12-01) -
HER2-Low Breast Cancer—Current Knowledge and Future Directions
by: Abeer M. Shaaban, et al.
Published: (2025-04-01) -
Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
by: Fangchao Zheng, et al.
Published: (2025-05-01) -
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)